文献速递支持与姑息治疗

威尼托肿瘤网络癌症患者SARS-CoV-2感染的流行病学与临床病程:ROVID研究

Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study.
PubMed 文献 · Eur J Cancer · 2021-02-03

体力状态、年龄、两种以上合并症、呼吸困难、COVID-19表型≥3、住院、ICU入住、中性粒细胞/淋巴细胞比值及血小板减少与死亡风险显著相关。

要点

  • 癌症合并SARS-CoV-2感染患者死亡率达33%,17%死因直接归因于感染。
  • 体力状态、年龄、≥2种合并症、呼吸困难及COVID-19表型≥3与死亡风险显著相关。
  • 住院、ICU入住、中性粒细胞/淋巴细胞比值及血小板减少亦与死亡风险显著相关。

核心结论

  • 本研究报告的死亡率印证了癌症患者群体的脆弱性,强调需保护癌症患者免于SARS-CoV-2感染。

研究设计与样本

  • ROVID为区域注册研究,纳入有癌症诊断且记录SARS-CoV-2感染的患者,收集癌症诊断、合并症、抗肿瘤治疗及感染相关数据,采用逻辑回归分析临床/实验室变量与全因死亡的关联。

主要发现

  • 与死亡风险显著相关的因素包括:ECOG体力状态、年龄、两种或以上合并症、呼吸困难、COVID-19表型≥3、住院、ICU入住、中性粒细胞/淋巴细胞比值及血小板减少。

临床怎么用

  • 对癌症患者应加强SARS-CoV-2感染防护,降低感染风险。
  • 评估癌症患者感染风险时关注体力状态、年龄、合并症数量、呼吸困难、COVID-19表型、住院及ICU入住、中性粒细胞/淋巴细胞比值和血小板减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Coronavirus disease 2019 (COVID-19) pandemic started in Italy with clusters identified in Northern Italy. The Veneto Oncology Network (Rete Oncologica Veneta) licenced dedicated guidelines to ensure proper care minimising the risk of infection in patients with cancer. Rete Oncologica Veneta covID19 (ROVID) is a regional registry aimed at describing epidemiology and clinical course of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with cancer. MATERIALS AND METHODS: Patients with cancer diagnosis and documented SARS-CoV-2 infection are eligible. Data on cancer diagnosis, comorbidities, anticancer treatments, as well as details on SARS-CoV-2 infection (hospitalisation, treatments, fate of the infection), have been recorded. Logistic regression analysis was applied to calculate the association between clinical/laboratory variables and death from any cause. RESULTS: One hundred seventy patients have been enrolled. The median age at time of the SARS-CoV infection was 70 years (25-92). The most common cancer type was breast cancer (n = 40). The majority of the patients had stage IV disease. Half of the patients had two or more comorbidities. The majority of the patients (78%) presented with COVID-19 symptoms. More than 77% of the patients were hospitalized and 6% were admitted to intensive care units. Overall, 104 patients have documented resolution of the infection. Fifty-seven patients (33%) have died. In 29 cases (17%), the cause of death was directly correlated to SARS-CoV-2 infection. Factors significantly correlated with the risk of death were the following: Eastern Cooperative Oncology Group performance status (PS), age, presence of two or more comorbidities, presence of dyspnoea, COVID-19 phenotype ≥ 3, hospitalisation, intensive care unit admission, neutrophil/lymphocyte ratio and thrombocytopenia. CONCLUSIONS: The mortality rate reported in this confirms the frailty of this population. These data reinforce the need to protect patients with cancer from SARS-CoV-2 infection.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Guarneri V, Bassan F, Zagonel V, et al. Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study. Eur J Cancer. 2021. PMID: 33647547. doi:10.1016/j.ejca.2021.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。